Biology subjects

Liddle, J.

Publications and source records attributed to Liddle, J..

4 recordsLinked to original sources

bioRxiv2026

Structural mechanism of TRPC3 inhibition by a potent and selective antagonist

The transient receptor channel canonical family member 3 (TRPC3) is a non-selective, calcium-permeable cation channel within the larger TRP superfamily. TRPC3 is expressed in both excitable and non-excitable cells, where it integrates multiple signaling pathways and is directly activated by binding of diacylglycerol following activation of G-protein coupled receptors. Increased TRPC3 signaling is implicated in several diseases, highlighting TRPC3 as a potential therapeutic target. However, the development of TRPC3 inhibitors with suitable potency and selectivity has been challenging due to the channels high structural and sequence homology with related family members, particularly TRPC6. Here, we present a novel, selective and highly potent TRPC3 antagonist (GSK2820986A) featuring an anilino-thiazole pharmacophore. Through a combination of molecular dynamic simulations and functional assays, we identify a putative binding site for GSK2820986A in the S4-S5 pocket and propose a potential inhibitory mechanism. Our findings provide a powerful tool compound and mechanistic framework to advance the investigation and therapeutic targeting of TRPC3 in disease.

biochemistry↗

bioRxiv2025

Discovery of an orally available potent ER aminopeptidase 1 (ERAP1) inhibitor that enhances anti-tumor responses and limits inflammatory autoimmunity in vivo.

Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an intracellular enzyme that can regulate immune responses primarily by proteolytically processing peptides before loading and presentation on the cell surface by major histocompatibility class I molecules (MHC-I). ERAP1 activity can either reduce the immunogenicity of cancer cells by over-trimming cancer-associated antigenic peptides or contribute to autoimmunity by generating self-antigenic peptides. As a result, ERAP1 inhibition has emerged as a tractable approach for cancer immunotherapy and specific classes of autoimmunity. Here, we describe the discovery, after hit-to-lead optimization, of a potent and selective ERAP1 inhibitor based on the pyrrolidine 3-carboxylic acid scaffold that targets the regulatory allosteric site. The compound has favourable in vivo pharmacokinetics, including oral bioavailability, and can regulate the immunopeptidome of cancer cells and enhance cancer cell antigenicity in vivo in a dose-dependent manner, controlling tumor growth. In addition, when administered in the murine collagen-induced arthritis model, it does not induce any exacerbation of autoimmune responses but rather results in a dose-dependent therapeutic benefit. Our results demonstrate that ERAP1 inhibition can constitute a tractable approach to modulating immune responses for therapeutic applications, providing mechanistic insight and a valuable lead and in vivo tool for further drug development efforts and for interrogating ERAP1 biology.

immunology↗

bioRxiv2024

Synaptic Proteomes of Cortical Interneuron Classes Revealed by Antibody Directed Proximity Labeling.

Subtypes of inhibitory interneurons play diverse roles within neural circuits in cerebral cortex. Defining the molecular underpinnings of interneuron functions within cortical circuits will require identification of interneuron synaptic proteomes. In this study, we first combined genetically directed expression of tdTomato-synaptophysin with antibody-directed proximity labeling and tandem mass spectrometry to identify synaptic proteomes of three major interneuron classes in mouse cortex: parvalbumin (PV), somatostatin (SS), and vasoactive intestinal peptide (VIP). After stringent filtering we identified 581 proteins: 228 identified in all cell classes and 353 in one or two of three classes. The PV class had the largest number of uniquely identified proteins (141), followed by VIP (30) and SST (20). Consistent with previously reported electrophysiological evidence, PV presynaptic proteomes were enriched for NMDA receptor subunits and scaffolding proteins. We used antibodies against synaptotagmin 2 (Syt2), a presynaptic protein present at PV synapses, to confirm NMDAR localization, and to find that the mu-opioid receptor agonist buprenorphine rapidly caused reorganization of the PV presynaptic proteome. Overall, our results reveal proteomes of PV, SST, and VIP interneurons in cortex that likely underlie distinct and dynamic interneuron synaptic properties.

neuroscience↗

bioRxiv2020

Development of a small molecule that corrects misfolding and increases secretion of Z α1-antitrypsin

Severe 1-antitrypsin deficiency results from the Z allele (Glu342Lys) that causes the accumulation of homopolymers of mutant 1-antitrypsin within the endoplasmic reticulum of hepatocytes in association with liver disease. We have used a DNA-encoded chemical library to undertake a high throughput screen to identify small molecules that bind to, and stabilise Z 1-antitrypsin. The lead compound blocks Z 1-antitrypsin polymerisation in vitro, reduces intracellular polymerisation and increases the secretion of Z 1-antitrypsin three-fold in mammalian cells including an iPSC model of disease. Crystallographic and biophysical analyses demonstrate that GSK716 and related molecules bind to a cryptic binding pocket, negate the local effects of the Z mutation and stabilise the bound state against progression along the polymerization pathway. Oral dosing of transgenic mice at 100 mg/kg three times a day for 20 days increased the secretion of Z 1-antitrypsin into the plasma by 7-fold. There was no observable clearance of hepatic inclusions with respect to controls. This study provides proof-of-principle that mutation ameliorating small molecules are a viable approach to treat protein conformational diseases.

pharmacology and toxicology↗